Featured Research

from universities, journals, and other organizations

Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect

Date:
March 11, 2013
Source:
University of Colorado Denver
Summary:
Studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells -- without affecting surrounding, healthy cells.

Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells -- without affecting surrounding, healthy cells.

The first study, published today in the journal Oncogene, worked with acute myeloid leukemia (AML), for which current chemotherapies offer a cure rate of only about 55 percent.

"In about 2/3 of all AML patients and about 90 percent of adult AML patients, we found that the Mer receptor was upregulated. Mer receptor protein shouldn't exist in normal myeloid cells, but we found it abnormally expressed," says Doug Graham, MD, PhD, investigator at the CU Cancer Center and associate professor of pediatrics and immunology at the University of Colorado School of Medicine.

The Mer receptor sits within the cell membrane, and when it becomes activated the cell receives signals to grow and survive. Leukemia and perhaps many solid cancers have taken advantage of Mer's cell survival function to assist the cancer's rampant proliferation. When Graham and colleagues used shRNA to silence the production of Mer in leukemia cells, they showed decreased leukemia cell survival, increased sensitivity to existing chemotherapies and longer survival in mouse models of leukemia.

A second study, published this month in Blood Cancer Journal, shows similar results with acute lymphoblastic leukemia (ALL), the most common pediatric cancer.

"The ALL cure rate is already over 80 percent, but for patients who relapse, the prognosis is much less optimistic. We need targeted therapies to use as second-line treatments for the population for whom existing therapies aren't lasting, particularly in patients with relapsed T cell ALL," Graham says.

Second, he points out that a quarter of pediatric ALL patients who respond to existing chemotherapies do so at the price of significant long-term side-effects. "And so in addition to increased survival, the second goal of targeted therapies is decreased side-effects," Graham says.

Inhibition of the Mer protein receptor is promising on both accounts.

"Not only do B-cell and T-cell leukemia cells die when you knock down Mer receptor expression, but these cells are also much more sensitive to existing chemotherapies. By hitting Mer, we're making the chemotherapy more effective," Graham says.

In ALL and AML, Graham's studies show that making Mer inhibition means that less chemotherapy may have equal or stronger effect. Strong preliminary evidence shows that Mer may be the key to less toxic, more effective therapies for leukemia.


Story Source:

The above story is based on materials provided by University of Colorado Denver. Note: Materials may be edited for content and length.


Journal References:

  1. A B Lee-Sherick, K M Eisenman, S Sather, A McGranahan, P M Armistead, C S McGary, S A Hunsucker, J Schlegel, H Martinson, C Cannon, A K Keating, H S Earp, X Liang, D DeRyckere, D K Graham. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene, 2013; DOI: 10.1038/onc.2013.40
  2. L N Brandao, A Winges, S Christoph, S Sather, J Migdall-Wilson, J Schlegel, A McGranahan, D Gao, X Liang, D DeRyckere, D K Graham. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2013; 3 (1): e101 DOI: 10.1038/bcj.2012.46

Cite This Page:

University of Colorado Denver. "Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect." ScienceDaily. ScienceDaily, 11 March 2013. <www.sciencedaily.com/releases/2013/03/130311091529.htm>.
University of Colorado Denver. (2013, March 11). Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2013/03/130311091529.htm
University of Colorado Denver. "Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect." ScienceDaily. www.sciencedaily.com/releases/2013/03/130311091529.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) — Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) — The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) — A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) — All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins